TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16569219

Group type: EXPERIMENTAL
Intervention: scFOS 2.5 g/d
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: scFOS 5 g/d
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: scFOS 7.5 g/d
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: scFOS 10 g/d
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: scFOS (all doses)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: scFOS 2.5 g/d and 5 g/d
Number of subjects: 200
Study: 12691651

Group type: EXPERIMENTAL
Intervention: Brånemark System TiUnite surface implants
Number of subjects: 44

Group type: COMPARATOR
Intervention: Brånemark System machined-surface implants
Number of subjects: 44
Study: 11890519

Group type: EXPERIMENTAL
Intervention: Oral phentolamine (Vasomax) 40 mg before sleep
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 9623694

Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) at 30 L x min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) at 60 L x min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) at 90 L x min(‐1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inspiratory flow rate (V'I) changes from 30 to 90 L x min(‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Comparison between LTP and QP groups
Number of subjects: 13
Study: 7841626

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula-fed infants with LCP-enriched formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formula-fed infants with commercially available formula without LCPs
Number of subjects: 0
Study: 2905588

Group type: EXPERIMENTAL
Intervention: Alfentanil combined with low concentrations of isoflurane (group 1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Alfentanil combined with higher concentrations of isoflurane (group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Isoflurane without opioids (group 3)
Number of subjects: 3
Study: 31880055

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (HP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide (CP)
Number of subjects: 50
Study: 31657594

Group type: EXPERIMENTAL
Intervention: Given-NIC (given nicotine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Told-NIC (told-nicotine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cigarette-related pictures
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Congruent trials (smoking or unpleasant)
Number of subjects: 40
Study: 27757553

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Droperidol 1.25 mg
Number of subjects: 186
Study: 25500485

Group type: EXPERIMENTAL
Intervention: New twice daily sustained-release (SR) paracetamol formulation (2 x 1,000 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Immediate-release (IR) paracetamol (2 x 500 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Extended-release (ER) paracetamol (2 x 665 mg)
Number of subjects: 28
Study: 23650792

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with cervical plexus block (EA+CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham electroacupuncture plus cervical plexus block (sham group)
Number of subjects: 40
Study: 21481542

Group type: EXPERIMENTAL
Intervention: Graphic-enhanced information
Number of subjects: 102

Group type: COMPARATOR
Intervention: Text-only information
Number of subjects: 102
Study: 19904268

Group type: EXPERIMENTAL
Intervention: RT‐5‐FU arm (5-fluorouracil 350 mg m(‐2) per day during radiotherapy)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RT‐GC arm (gemcitabine 300 mg m(‐2) and cisplatin 30 mg m(‐2) on days 1, 8, 22, and 29)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: RT‐GC+GC arm (same concurrent treatment followed by sequential full-dose gemcitabine 1000 mg m(‐2) and cisplatin 50 mg m(‐2) every 2 weeks)
Number of subjects: 95
Study: 17013570

Group type: EXPERIMENTAL
Intervention: Quality assurance program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dummy run procedure
Number of subjects: 0
Study: 15310642

Group type: EXPERIMENTAL
Intervention: Morphine PCA plus a background infusion (group PCA-B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine PCA alone (group PCA-A)
Number of subjects: 60
Study: 11123499

Group type: EXPERIMENTAL
Intervention: Paeoniae Radix (1.2 g extract powder once daily for 7 days) + 200 mg VPA on day 7
Number of subjects: 6

Group type: COMPARATOR
Intervention: 200 mg VPA gastro-resistant tablet alone on day 7
Number of subjects: 6
Study: 9569797

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 25

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 25
Study: 8436990

Group type: EXPERIMENTAL
Intervention: Arteriovenous impulse system (pumped group)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard thrombosis prophylaxis (nonpumped group)
Number of subjects: 74
Study: 31738372

Group type: EXPERIMENTAL
Intervention: Minocycline 400 mg/d
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/d
Number of subjects: 554

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Combined Minocycline (400 mg/d and 200 mg/d)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Minocycline 400 mg/d vs 200 mg/d
Number of subjects: 554
Study: 31454264

Group type: EXPERIMENTAL
Intervention: Arginine (1.5% arginine, fluoride-free)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Fluoride (1,100 ppm F/NaF)
Number of subjects: 83
Study: 29157230

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 0
Study: 26700994

Group type: EXPERIMENTAL
Intervention: Taiwanese mother‐friendly childbirth model (experimental group)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Routine prenatal care (control group)
Number of subjects: 751
Study: 24024532

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine or Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine or Venlafaxine
Number of subjects: 0
Study: 21288346

Group type: EXPERIMENTAL
Intervention: Internet intervention providing an information module and an e-coach module.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group with access to a website with hyperlinks to commonly available information only.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 170
Study: 18256066

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 16178655

Group type: COMPARATOR
Intervention: Normal colon mucosa/submucosa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adenomatous colon mucosa/submucosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal colon muscle layer/chorion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adenomatous colon muscle layer/chorion
Number of subjects: 0
Study: 14641990

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg or 500 mg daily) in combination with carboplatin/paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg or 500 mg daily) in combination with cisplatin/gemcitabine
Number of subjects: 0
Study: 10385666

Group type: EXPERIMENTAL
Intervention: Consensus interferon (CIFN) or interferon (IFN) alfa‐2b for 6 months
Number of subjects: 472
Study: 8875441

Group type: COMPARATOR
Intervention: Sleep deprivation group (16 subjects)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sleeping group (16 subjects)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Age as a predictor in sleep-deprived subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Subjective sleepiness and drowsiness measures
Number of subjects: 32
Study: 1686851

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6336891

Group type: EXPERIMENTAL
Intervention: Orgotein (4 mg a week for six weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Methylprednisolone acetate (4 mg a week for six weeks)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Orgotein
Number of subjects: 28
Study: 30617724

Group type: EXPERIMENTAL
Intervention: Sodium monensin (MON; Rumensin® 200, Elanco Animal Health, Brazil) @ 0.6 mg/kg of body weight for 90 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Total mixed ration without supplementation (CON)
Number of subjects: 100
Study: 30047502

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 225

Group type: COMPARATOR
Intervention: Conventional evidence-based therapy
Number of subjects: 225
Study: 27319407

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage once per week for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 24510512

Group type: EXPERIMENTAL
Intervention: Dark roast coffee blend
Number of subjects: 9

Group type: COMPARATOR
Intervention: Market blend coffee
Number of subjects: 9
Study: 21885990

Group type: EXPERIMENTAL
Intervention: Short-term statin pretreatment (3-7 days) with rosuvastatin (hydrophilic statin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term statin pretreatment (3-7 days) with atorvastatin (lipophilic statin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ischemia and reperfusion (IR)
Number of subjects: 0
Study: 19280548

Group type: EXPERIMENTAL
Intervention: 22G IVC
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 20G IVC
Number of subjects: 91

Group type: COMPARATOR
Intervention: In vitro testing
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: In vivo testing
Number of subjects: 91
Study: 17591488

Group type: EXPERIMENTAL
Intervention: Laser-scanning confocal microscopy (LCM)
Number of subjects: 15
Study: 15365307

Group type: EXPERIMENTAL
Intervention: Naltrexone (titrated to 50 mg/day)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Nalmefene (titrated to 40 mg/day)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Alcohol (0.4 mg/kg for men, 0.34 mg/kg for women)
Number of subjects: 215
Study: 11407649

Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg sc)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9739219

Group type: EXPERIMENTAL
Intervention: Single-incision technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Two-incision technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study: 7528949

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (Trasylol)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 2499036

Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Conversion from CsA to Aza
Number of subjects: 80
Study: 29495908

Group type: EXPERIMENTAL
Intervention: Long noncoding RNA (lncRNA) expression levels in endometrium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 50
Study: 29056121

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel clipless group (HSG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC) with electrocautery group
Number of subjects: 150
Study: 24611630

Group type: EXPERIMENTAL
Intervention: Pilates course (12 weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 23482762

Group type: EXPERIMENTAL
Intervention: PapCone® sampling method
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional sampling method (Ayre's spatula plus cytobrush)
Number of subjects: 18
Study: 21808115

Group type: EXPERIMENTAL
Intervention: Pleural tubes inserted through the sixth intercostal space at the midaxillary line (IC6, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rigid straight pleural tubes inserted from the mediastinum through the subxiphoid area (SX‐r, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soft curved drainage tubes inserted from the mediastinum through the subxiphoid area (SX‐s, n=20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study: 19715976

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with stepwise reduction of CNI
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (maintenance CNI dose)
Number of subjects: 90
Study: 17013995

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine (400 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibuprofen-arginine
Number of subjects: 20
Study: 12881035

Group type: EXPERIMENTAL
Intervention: Pretest as a covariate in the model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posttest and follow-up analysis
Number of subjects: 0
Study: 11021450

Group type: EXPERIMENTAL
Intervention: Uncemented fixation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cemented fixation
Number of subjects: 28
Study: 8795673

Group type: EXPERIMENTAL
Intervention: Continuous flow oxygen
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Demand oxygen delivery system (DODS)
Number of subjects: 15
Study: 1618199

Group type: EXPERIMENTAL
Intervention: Circadian pattern of MI incidence
Number of subjects: 12163

Group type: EXPERIMENTAL
Intervention: Circadian pattern of MI incidence in diabetics
Number of subjects: 12163
Study: 6360786

Group type: EXPERIMENTAL
Intervention: 10-micrograms doses of 15-R-15 methyl prostaglandin E2 for 24 h before treatment with aspirin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31120674

Group type: EXPERIMENTAL
Intervention: Vatinoxan (117-297 μg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study: 30538080

Group type: EXPERIMENTAL
Intervention: Cold application to median nerve at wrist
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no cold application)
Number of subjects: 15
Study: 26923088

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Spontaneous Healing (SH)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 26350482

Group type: EXPERIMENTAL
Intervention: Interactive safety decision aid web-based and smartphone application (App) for abused college women and their friends
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual safety planning control website/App
Number of subjects: 600
Study: 23554974

Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine (TIV)
Number of subjects: 0
Study: 21382439

Group type: EXPERIMENTAL
Intervention: Social Inclusion (SI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Social Exclusion (SE)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both conditions (SI and SE)
Number of subjects: 55
Study: 19398930

Group type: COMPARATOR
Intervention: Probiotic supplementation (preventive effects)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Probiotic supplementation (therapeutic role)
Number of subjects: 632
Study: 17926616

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture TENS group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupoints TENS group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-abdominal acupuncture TENS group
Number of subjects: 120
Study: 15276091

Group type: EXPERIMENTAL
Intervention: Microalbuminuria (n=28)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Normoalbuminuria (n=115)
Number of subjects: 143
Study: 11844641

Group type: EXPERIMENTAL
Intervention: Glutamine (80 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine (2.5 mM) in isolated rat heart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glutamate (2.5 mM) in isolated rat heart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspartate (2.5 mM) in isolated rat heart
Number of subjects: 0
Study: 9671862

Group type: EXPERIMENTAL
Intervention: Alfuzosin, 2.5 mg three times daily for 3 months, followed by maintenance of alfuzosin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Alfuzosin, 2.5 mg three times daily for 3 months, followed by alfuzosin every other day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Discontinuation of alfuzosin (no treatment)
Number of subjects: 79
Study: 7670424

Group type: EXPERIMENTAL
Intervention: Electronic thermography
Number of subjects: 18
Study: 2659560

Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 14
Study: 31754852

Group type: EXPERIMENTAL
Intervention: 3D TAPP laparoscopic approach
Number of subjects: 278

Group type: COMPARATOR
Intervention: 2D TAPP laparoscopic approach
Number of subjects: 278
Study: 29910120

Group type: EXPERIMENTAL
Intervention: CRT + MRIGE (computerized social cognition training)
Number of subjects: 131

Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: CRT + MRIGE
Number of subjects: 131
Study: 28877729

Group type: EXPERIMENTAL
Intervention: Enhanced feedback (monthly written feedback incorporating goal setting and action planning delivered by a senior clinical coordinator)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard feedback (2‐monthly written feedback on multiple quality of pediatric care indicators)
Number of subjects: 12
Study: 27002696

Group type: EXPERIMENTAL
Intervention: Antiviral therapy and surgical procedures
Number of subjects: 56

Group type: COMPARATOR
Intervention: Dental treatment, local and systemic keratoplastic formulations
Number of subjects: 56
Study: 23437816

Group type: EXPERIMENTAL
Intervention: Phantom shocks (PS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Objective shocks only (OSO)
Number of subjects: 17
Study: 21284476

Group type: EXPERIMENTAL
Intervention: CSII/RT‐CGM with the algorithm (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CSII/RT‐CGM without algorithm (Group B)
Number of subjects: 60
Study: 20035590

Group type: EXPERIMENTAL
Intervention: Slow titration schedule, 1.4 mg/kg/day
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Slow titration schedule, 0.8 mg/kg/day
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Fast titration schedule, 1.4 mg/kg/day
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Fast titration schedule, 0.8 mg/kg/day
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Both maintenance treatment groups (0.8 mg/kg/day and 1.4 mg/kg/day)
Number of subjects: 267
Study: 16498932

Group type: EXPERIMENTAL
Intervention: Radiologically guided technique (group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anatomical landmark method (group 1)
Number of subjects: 80
Study: 15162466

Group type: EXPERIMENTAL
Intervention: IL-2Rab (basiliximab) 20 mg intravenously within 6 hours of graft reperfusion and on postoperative day 4
Number of subjects: 31

Group type: COMPARATOR
Intervention: Steroid group (standard immunosuppressive regimen with tacrolimus and corticosteroid), n = 49
Number of subjects: 31
Study: 10985600

Group type: EXPERIMENTAL
Intervention: Aerobic Training Group (ATG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Resistance Training Group (RTG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cross-Training Group (XTG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 48
Study: 9568337

Group type: EXPERIMENTAL
Intervention: Povidone iodine plus neosporin (PVP + N)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Silver sulphadiazine (SSD)
Number of subjects: 1053
Study: 8403178

Group type: EXPERIMENTAL
Intervention: Bupivacaine-lidocaine mixture, pH 6.7 with hyaluronidase (10 units.ml-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture, pH 3.9
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture with hyaluronidase, pH 5.1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture alkalinized to pH 5.1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine-lidocaine mixture alkalinized to pH 6.7
Number of subjects: 100
Study: 6752875

Group type: EXPERIMENTAL
Intervention: Pirprofen 800 mg/day
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ketoprofen 300 mg/day
Number of subjects: 183
Study: 31512550

Group type: EXPERIMENTAL
Intervention: Night Time Recharge (NTR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27785747

Group type: EXPERIMENTAL
Intervention: Chronic alkali therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: No chronic alkali therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy male age-matched volunteers
Number of subjects: 200
Study: 24917531

Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy (SAH)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 319
Study: 23675985

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (100 mJ, 85 J/cm² per pulse with a quartz fiber of 400 μm, in scanning movements)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: In-office prophylaxis with pumice
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: In-office Colgate Sensitive Pro-Relief™ Desensitizing Paste
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48
Study: 21402619

Group type: EXPERIMENTAL
Intervention: C-PLD (carboplatin-pegylated liposomal doxorubicin)
Number of subjects: 157

Group type: COMPARATOR
Intervention: C-P (carboplatin-paclitaxel)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: C-PLD
Number of subjects: 157

Group type: COMPARATOR
Intervention: C-P
Number of subjects: 157
Study: 19541594

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 16953366

Group type: EXPERIMENTAL
Intervention: beta-alanine plus creatine (CrBA)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: creatine (Cr)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: beta-alanine (beta-Ala)
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo (PL)
Number of subjects: 55